Genetic Counseling for Patients with Non-Clear Cell RCC
The panel closes their discussion with a look at the standards for genetic counseling for patients with non-clear cell RCC.
Read More
Best Approaches and Emerging Data in the Treatment of Non-Clear Cell RCC
The panel discusses the best approaches to treating patients with non-clear cell RCC.
Read More
Preferred Treatment Regimens for Refractory RCC
The panel shares their preferred treatment regimens for patients with refractory renal cell carcinoma.
Read More
Patient Profile Presentation: A 47-Year-Old Male With Refractory RCC
Hans Hammers, MD, presents a profile of a 47-year-old male with refractory renal cell carcinoma.
Read More
Updates in the Adjuvant Treatment of Metastatic RCC
The panel discusses recent clinical trial data in the adjuvant treatment of metastatic renal cell carcinoma.
Read More
Reviewing Data in Frontline Metastatic RCC Treatment from the COSMIC-313 Trial
Drs Moshe Ornstein and Hans Hammers review data from the COSMIC-313 trial investigating ipilimumab, nivolumab, and cabozantinib for the frontline treatment of metastatic renal cell carcinoma.
Read More
Novel Doublet Combination Therapies in First-Line Metastatic RCC Treatment
The panel provides an overview of novel double combination therapies currently under investigation.
Read More
Treatment Approaches for Patients with RCC and Bone Metastases
Mehmet Asim Bilen, MD, details how he approaches IO/TKI therapy for patients with renal cell carcinoma with bone metastases.
Read More
The panel discusses the use of quality-of-life clinical trial data in metastatic renal cell carcinoma and how liver and brain metastases affect treatment decision-making.
Read More
Considerations When Deciding Between an IO/TKI and IO/IO Treatment Regimen for a Patient With RCC
Hans Hammers, MD, PhD, explains the situations in which he would choose an ipilimumab/nivolumab treatment regimen over one of the discussed IO/TKI regimens.
Read More
Drs Moshe Ornstein and Mehmet Asim Bilen review updated data from the CheckMate 9ER and CLEAR trials investigating combination treatments for metastatic renal cell carcinoma.
Read More
Patient Profile Presentation: A 65-Year-Old Woman With Metastatic RCC
Mehmet Asim Bilen, MD, presents a profile of a 65-year-old woman with metastatic renal cell carcinoma for discussion.
Read More
Risk Stratification of Patients with Metastatic Renal Cell Carcinoma (RCC)
Moshe Ornstein, MD, MA, starts a conversation on how patients with metastatic renal cell carcinoma are classified by risk, and how risk category influences approaches to systemic therapy.
Read More
Biomarker Dilemma Persists With Immunotherapy in Bladder Cancer
May 15th 2018The quest continues to identify a predictive biomarker of response to more precisely treat patients with checkpoint inhibitors that, while markedly beneficial to some patients, are not without their own costs and associated immune-related adverse effects.
Read More